Medicare GLP-1 Eligibility Checker 2026: Do You Qualify for $50/Month?
Answer 6 quick questions to see if you qualify for Medicare's new Bridge Program, which has covered Wegovy, Zepbound, and Foundayo at $50/month since July 1, 2026.
Medically reviewed by Dr. A. Goher, MD · Takes about 2 minutes · Not medical advice.
Are you 65 or older, or eligible for Medicare due to a qualifying disability?
The Medicare Bridge Program is only available to Medicare beneficiaries.
About the Medicare Bridge Program
Since July 1, 2026, Medicare has run the Bridge Program — a historic expansion of coverage for GLP-1 weight-loss medications. For eligible beneficiaries, brand-name drugs like Wegovy, Zepbound, and the newly approved oral Foundayo (orforglipron) are available for a flat $50/month copay — a dramatic reduction from the $1,000+ retail price.
Who qualifies?
- Medicare beneficiaries age 65+, or under 65 with qualifying disability
- Enrolled in Medicare Part D or Medicare Advantage with drug coverage
- BMI of 35 or higher; or BMI 30+ with heart failure, uncontrolled hypertension or chronic kidney disease; or BMI 27+ with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease
- Documented 3+ months of diet and exercise intervention
- No contraindications (MTC, MEN2, pancreatitis, active cancer)
What drugs are covered at $50/month?
- Wegovy (semaglutide) — weekly injection from Novo Nordisk
- Zepbound (tirzepatide) — weekly injection from Eli Lilly
- Foundayo (orforglipron) — daily oral pill, FDA approved April 2026
How to enroll
- Confirm your Medicare Part D or MA-PD enrollment on medicare.gov
- Schedule an appointment with your primary care physician
- Document your BMI, weight history, and any comorbidities
- Request a Bridge Program prescription (the program has been live since July 1, 2026)
- Fill at any Medicare-participating pharmacy for $50/month
This tool provides general guidance only and does not constitute medical advice. Final eligibility is determined by your Medicare plan and prescriber. Always consult a licensed healthcare provider. Medically reviewed by Dr. A. Goher, MD.